Add like
Add dislike
Add to saved papers

The Projected Economic and Health Burden of Uncontrolled Asthma in the United States.

RATIONALE: Despite effective treatments, a large proportion of asthma patients do not achieve sustained asthma control. The 'preventable' burden associated with lack of proper control is likely taking a high toll at the personal and population level.

OBJECTIVE: We predicted the future excess health and economic burden associated with uncontrolled asthma among American adolescents and adults for the next 20 years.

METHODS: We built a probabilistic model that linked state-specific estimates of population growth and aging, asthma prevalence, and asthma control levels. We conducted several meta-analyses to estimate the adjusted differences in healthcare resource use, quality-adjusted life years (QALYs), and productivity loss across control levels. We projected, nationally and at the state-level, total direct and indirect (due to productivity loss) costs (in 2018 dollars) and QALYs lost due to uncontrolled asthma from 2019 to 2038.

MEASUREMENTS AND MAIN RESULTS: Total 20-year direct costs associated with uncontrolled asthma are estimated to be $300.6 billion (95% confidence interval [CI] $190.1-$411.1). When indirect costs are added, total economic burden will be $963.5 billion (95%CI $664.1B-$1,262.9B). American adolescents and adults will lose an estimated 15.46 million (95%CI 12.77M-18.14M) QALYs over this period due to uncontrolled asthma.

CONCLUSION: The burden of uncontrolled asthma is substantial and will continue to grow. Given that a substantial fraction of this burden is preventable, better adherence to evidence-informed asthma management strategies by care providers and patients has the potential to substantially reduce costs and improve quality of life. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app